Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 235

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 235
---
na Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. ZTlido Formulary Coverage - Over 90% of Lives Covered or In Negotiation We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying out-of-pocket.With the co-payassistance program, qualifying patients do not have to pay any co-paymentfor their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. Clinical Development Overview ZTlido Clinical Trial Highlights We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido:

| • |     | demonstrated bioequivalence to Lidoderm in study 
 SCI-LIDO-PK-002A;                                |

| • |     | showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the 12-hour administration period in study SCI-LIDO-ADH-001; |

| • |     | showed superior adhesion to Lidoderm and Mylan’s generic lidocaine patch in studies SCI-LIDO-AHD-002 and 
 SCI-LIDO-ADH-003;                                                                                        |

| • |     | was not meaningfully impacted by heat or exercise in study SCI-LIDO-HEX-001; |

| • |     | was able to be used under showering and bathing conditions in study SCI-LIDO-ADH-004; and |

| • |     | did not show clinically meaningful dermal irritation in study SCI-LIDO-DERM-001. |

154

ZTlido Study Details

Pivotal Bioequivalence Study-